Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine

Journal of Medical Virology

Volumn 82, Issue 10, 2010, Pages 1629-1634

  Bovier, Patrick A ^a   Bock, Jürgen ^b   Ebengo, Tiziana Farinelli ^a   Frösner, Gert ^c,f   Glaus, Jacqueline ^d   Herzog, Christian ^e   Loutan, Louis ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Maximilians University ^*

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e CRUCELL HOLLAND BV   (Netherlands)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Hepatitis A; Immunogenicity; Long term protection; Mathematical models; Vaccine; Virosomes

Indexed keywords

ALUMINUM; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE;

ADOLESCENT; ADULT; ARTICLE; FEMALE; FOLLOW UP; HEPATITIS A; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; NUCLEOTIDE SEQUENCE; PREDICTION; SEROLOGY; VACCINATION;

HEPATITIS A VIRUS;

EID: 77956580935     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21883     Document Type: Article

References (24)

1. Berger R, Just M, Althaus B. 1993. Time course of hepatitis A antibody production after active, passive and active/passive immunisation: The results are highly dependent on the antibody test system used. J Virol Methods 43:287-297.
2. Bovier PA, Althaus B, Glueck R, Chippaux A, Loutan L. 1999. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J Travel Med 6:228-233.
3. Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. 2002. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 68:489-493.
4. Bovier PA, Farinelli T, Loutan L. 2005. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Vaccine 23:2424-2429.
5. Centers for Disease Control Prevention. 2006. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 55:1-23.
6. Cook IF. 2008. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 26:3551-3555.
7. D'Acremont V, Herzog C, Genton B. 2006. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J Travel Med 13:78-83.
8. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. 2005. Incidence of hepatitis A in Israel following universal immunization of toddlers. J Am Med Assoc 294:202-210.
9. Diaz-Mitoma F, Law B, Subramanya A, Hoet B. 2008. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine 26:1759-1763.
10. Glück R, Moser C, Metcalfe IC. 2004. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin Biol Ther 4:1139-1145.
11. Hammitt LL, Bulkow L, Hennessy TW, Zanis C, Snowball M, Williams JL, Bell BP, McMahon B. 2008. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis 198:1776-1782.
12. Lopalco PL, Prato R, Chironna M, Germinario C, Quarto M. 2008. Control of hepatitis a by universal vaccination of adolescents, Puglia, Italy. Emerg Infect Dis 14:526-528.
13. Loutan L, Bovier P, Althaus B, Gluck R. 1994. Inactivated virosome hepatitis A vaccine. Lancet 343:322-324.
14. Mayorga Perez O, Herzog C, Zellmeyer M, Loaisiga A, Frosner G, Egger M. 2003. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: Randomized placebo-controlled trial. J Infect Dis 188:671-677.
15. Moser C, Amacker M, Kammer AR, Rasi S, Westerfeld N, Zurbriggen R. 2007. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev Vaccines 6:711-721.
16. Pinheiro JC, Bates DM. 2000. Mixed effect models in S and S-Plus. New York, Berlin, Heidelberg: Springer.
17. Usonis V, Bakasenas V, Valentelis R, Katiliene G, Vidzeniene D, Herzog C. 2003. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine 21:4588-4592.
18. Van Damme P, Banatvala J, Fay O, Iwasson S, McMahon B, Van Herck K, Shouval D, Bonanni P, Connor G, Leroux-Roels G, Von Sonnenburg I. 2003. Hepatitis A booster vaccination: Is there a need? Lancet 362: 1065-1071.
19. van der Ploeg R, Beck BR, Frösner G, Hunt M, Herzog C, Hatz C. 2007. Successful booster response 8 to 11 years after a single primary vaccination with a virosome-formulated hepatitis A vaccine (Epaxal®). 10th CISTM, Vancouver, 2007 (abstracts).
20. Van Herck K, Van Damme P, Lievens M, Stoffel M. 2004. Hepatitis A vaccine: Indirect evidence of immune memory 12 years after the primary course. J Med Virol 72:194-196.
21. Verbeke G, Molenberghs G. 2000. Linear mixed models for longitudinal data. New York, Berlin, Heidelberg: Springer.
22. Vogt TM, Wise ME, Bell BP, Finelli L. 2008. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis 197:1282-1288. (Pubitemid 351632759)
23. Wasley A, Samandari T, Bell BP. 2005. Incidence of hepatitis A in the United States in the era of vaccination. J Am Med Assoc 294:194-201.
24. Wasley A, Fiore A, Bell BP. 2006. Hepatitis A in the era of vaccination. Epidemiol Rev 28:101-111.